User contributions
Jump to navigation
Jump to search
- 22:52, 6 December 2022 diff hist +4 m Melanoma →Pembrolizumab monotherapy {{#subobject:0a3e71|Regimen=1}}
- 16:30, 6 December 2022 diff hist +104 Melanoma →Pembrolizumab monotherapy {{#subobject:0a3e71|Regimen=1}}
- 16:26, 6 December 2022 diff hist +1,708 Melanoma →Neoadjuvant response criteria
- 14:12, 3 August 2022 diff hist +38 m User:Ryannguyen personal page update current Tag: visualeditor
- 15:23, 3 April 2022 diff hist +359 Melanoma →Nivolumab & Relatlimab {{#subobject:6abj1d|Regimen=1}}
- 15:19, 3 April 2022 diff hist +539 Melanoma →Pembrolizumab monotherapy {{#subobject:0a3e71|Regimen=1}}
- 01:30, 30 January 2022 diff hist +1 m Melanoma →Ipilimumab & Nivolumab {{#subobject:51gu10|Regimen=1}}
- 02:58, 28 January 2022 diff hist +1,886 Melanoma, BRAF-mutated →Advanced or metastatic disease, BRAF inhibitor-naive
- 02:39, 28 January 2022 diff hist +2,493 Uveal melanoma →Metastatic or unresectable disease
- 02:21, 28 January 2022 diff hist +116 Melanoma →Pembrolizumab monotherapy {{#subobject:0a3e71|Regimen=1}}
- 02:16, 28 January 2022 diff hist +644 Melanoma →References
- 02:14, 28 January 2022 diff hist +1,590 Melanoma →Metastatic or unresectable disease, second-line
- 02:01, 28 January 2022 diff hist +1,449 Melanoma →Metastatic or unresectable disease, first-line
- 02:08, 11 July 2021 diff hist +1,489 Esophageal squamous cell carcinoma →Metastatic or locally advanced disease, first-line
- 01:55, 11 July 2021 diff hist +44 Esophageal squamous cell carcinoma →Ipilimumab & Nivolumab {{#subobject:62bagc|Regimen=1}}
- 01:46, 11 July 2021 diff hist 0 m Esophageal squamous cell carcinoma →Cisplatin, Paclitaxel, Camrelizumab {{#subobject:5d50ee|Regimen=1}}
- 01:46, 11 July 2021 diff hist +117 Esophageal squamous cell carcinoma →Cisplatin & Paclitaxel {{#subobject:5d50ee|Regimen=1}}
- 01:44, 11 July 2021 diff hist +116 Esophageal squamous cell carcinoma →Cisplatin, Paclitaxel, Camrelizumab {{#subobject:5d50ee|Regimen=1}}
- 03:50, 26 April 2021 diff hist +3,695 Esophageal adenocarcinoma →Metastatic or locally advanced disease, first-line
- 03:09, 26 April 2021 diff hist +1,838 Colon cancer →Therapy for oligometastatic disease, including perioperative therapy and hyperthermic intra-peritoneal chemotherapy
- 22:54, 23 April 2021 diff hist +1,774 Colorectal cancer, HER2-positive →Advanced or metastatic disease, second or third-line therapy
- 20:14, 24 March 2021 diff hist 0 Esophageal cancer →Cisplatin & Paclitaxel {{#subobject:5d50ee|Regimen=1}}
- 20:13, 24 March 2021 diff hist 0 m Esophageal cancer →Cisplatin, Docetaxel, RT {{#subobject:21719f|Regimen=1}}
- 20:13, 24 March 2021 diff hist 0 Esophageal cancer →Fluorouracil, Oxaliplatin, RT {{#subobject:94b79a|Regimen=1}}
- 20:10, 24 March 2021 diff hist 0 Esophageal cancer →Cisplatin & Fluorouracil (CF) {{#subobject:37e6ba|Regimen=1}}
- 22:40, 22 March 2021 diff hist +1,268 Esophageal squamous cell carcinoma →Cisplatin, Fluorouracil, Cetuximab {{#subobject:717dc4|Regimen=1}}
- 22:40, 22 March 2021 diff hist -1,102 Esophageal cancer →Cisplatin & Paclitaxel {{#subobject:5d50ee|Regimen=1}}
- 22:37, 22 March 2021 diff hist +2,204 Esophageal squamous cell carcinoma →Definitive therapy
- 22:36, 22 March 2021 diff hist -1,936 Esophageal cancer →Cisplatin, Docetaxel, RT {{#subobject:21719f|Regimen=1}}
- 22:34, 22 March 2021 diff hist +2,102 Esophageal squamous cell carcinoma
- 22:34, 22 March 2021 diff hist -1,619 Esophageal cancer →Neoadjuvant chemoradiotherapy
- 22:23, 22 March 2021 diff hist -3,308 Esophageal cancer →Pembrolizumab monotherapy {{#subobject:c798a3|Regimen=1}}
- 22:22, 22 March 2021 diff hist -1,830 Esophageal cancer →Nivolumab monotherapy {{#subobject:10ee99|Regimen=1}}
- 22:22, 22 March 2021 diff hist -957 Esophageal cancer →Regimen variant #2, 75 mg/m2, indefinite {{#subobject:abe193|Variant=1}}
- 22:22, 22 March 2021 diff hist -1,230 Esophageal cancer →Etoposide monotherapy {{#subobject:344c29|Regimen=1}}
- 22:21, 22 March 2021 diff hist -2,322 Esophageal cancer →Cisplatin, Fluorouracil, Cetuximab {{#subobject:717dc4|Regimen=1}}
- 22:20, 22 March 2021 diff hist -3,801 Esophageal cancer →Cisplatin & Fluorouracil (CF) {{#subobject:4d9936|Regimen=1}}
- 22:19, 22 March 2021 diff hist -1,617 Esophageal cancer →Cisplatin & Docetaxel {{#subobject:724868|Regimen=1}}
- 22:18, 22 March 2021 diff hist -1,855 Esophageal cancer →Fluorouracil & Paclitaxel {{#subobject:58ub68|Regimen=1}}
- 22:16, 22 March 2021 diff hist -2,096 Esophageal cancer →Fluorouracil, Paclitaxel, RT {{#subobject:52e768|Regimen=1}}
- 22:12, 22 March 2021 diff hist -1,846 Esophageal cancer →Neoadjuvant induction therapy
- 22:10, 22 March 2021 diff hist +116 Esophageal cancer →Regimen {{#subobject:d18acj2|Variant=1}}
- 15:33, 17 March 2021 diff hist +47 Esophageal cancer
- 15:30, 17 March 2021 diff hist +23,324 N Esophageal squamous cell carcinoma Created page with "{| class="wikitable" style="text-align:center; width:100%;" ! colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c" |'''Page editor''' ! col..."
- 01:22, 17 December 2020 diff hist -14 Esophageal cancer →Regimen {{#subobject:d18acj2|Variant=1}}
- 01:08, 17 December 2020 diff hist +7 Esophageal cancer →Regimen {{#subobject:d18acj2|Variant=1}}
- 00:52, 17 December 2020 diff hist +2,000 Esophageal cancer →Metastatic or locally advanced disease, first-line
- 15:54, 22 July 2020 diff hist 0 Esophageal cancer →Regimen {{#subobject:d1dde0|Variant=1}}
- 15:53, 22 July 2020 diff hist +48 m Esophageal cancer →Regimen {{#subobject:d1dde0|Variant=1}}
- 15:52, 22 July 2020 diff hist -18 m Esophageal cancer →Regimen {{#subobject:d1dde0|Variant=1}}
- 15:51, 22 July 2020 diff hist +81 Esophageal cancer →Regimen {{#subobject:d1dde0|Variant=1}}
- 15:50, 22 July 2020 diff hist +1,327 Esophageal cancer →Metastatic or locally advanced disease, subsequent lines of therapy
- 12:49, 22 July 2020 diff hist +1,565 Colon cancer →Advanced or metastatic disease, first-line
- 12:29, 22 July 2020 diff hist +42 Colon cancer, RAS wild-type →References
- 12:11, 22 July 2020 diff hist +2,006 Colorectal cancer, BRAF-mutated →Advanced or metastatic disease, second or third-line therapy
- 12:03, 22 July 2020 diff hist -9 Colon cancer →Durvalumab & tremelimumab {{#subobject:8bb0ed|Regimen=1}}
- 12:03, 22 July 2020 diff hist +179 Colon cancer →Durvalumab & tremelimumab {{#subobject:8bb0ed|Regimen=1}}
- 21:25, 21 July 2020 diff hist +1,515 Colon cancer →Advanced or metastatic disease, subsequent lines of therapy
- 20:59, 21 July 2020 diff hist +74 Colon cancer →References
- 19:43, 21 July 2020 diff hist +1,508 Colon cancer →Advanced or metastatic disease, subsequent lines of therapy
- 18:59, 5 April 2020 diff hist +2,126 COVID-19 coronavirus and cancer →Scientific Evidence on COVID-19 Occurrence in Cancer Patients Tag: visualeditor
- 14:10, 22 March 2020 diff hist +636 COVID-19 coronavirus and cancer →General cancer Tag: visualeditor
- 15:24, 21 March 2020 diff hist +2,442 COVID-19 coronavirus and cancer →Oncology Tag: visualeditor
- 14:59, 21 March 2020 diff hist +630 COVID-19 coronavirus and cancer →Lopinavir and Ritonavir Tag: visualeditor
- 20:56, 20 March 2020 diff hist -10 m COVID-19 coronavirus and cancer →Tocilizumab Tag: visualeditor
- 20:56, 20 March 2020 diff hist +909 COVID-19 coronavirus and cancer →Tocilizumab Tag: visualeditor
- 20:32, 20 March 2020 diff hist +902 COVID-19 coronavirus and cancer →Hydroxychloroquine Tag: visualeditor
- 20:18, 20 March 2020 diff hist +374 COVID-19 coronavirus and cancer →Remdesivir Tag: visualeditor
- 00:22, 9 January 2020 diff hist -46 Non-small cell lung cancer, EGFR-mutated →Biomarker Eligibility Criteria
- 00:19, 9 January 2020 diff hist -35 Non-small cell lung cancer, EGFR-mutated →Carboplatin & Gemcitabine {{#subobject:8669e|Regimen=1}}
- 00:16, 9 January 2020 diff hist +42 Non-small cell lung cancer, EGFR-mutated →Regimen {{#subobject:bce236|Variant=1}}
- 00:12, 9 January 2020 diff hist +252 Non-small cell lung cancer, EGFR-mutated →Biomarker Eligibility Criteria
- 23:58, 8 January 2020 diff hist +99 Non-small cell lung cancer, EGFR-mutated →Variant #2, 40 mg/day {{#subobject:130d4a|Variant=1}}
- 23:52, 8 January 2020 diff hist +113 Non-small cell lung cancer, EGFR-mutated →Gefitinib monotherapy {{#subobject:4383b8|Regimen=1}}
- 23:51, 8 January 2020 diff hist +1 Non-small cell lung cancer, EGFR-mutated →Biomarker Eligibility Criteria
- 23:50, 8 January 2020 diff hist +112 Non-small cell lung cancer, EGFR-mutated →Cisplatin & Vinorelbine {{#subobject:ab1b88|Regimen=1}}
- 23:41, 8 January 2020 diff hist +31 Non-small cell lung cancer, BRAF-mutated →Dabrafenib & Trametinib {{#subobject:05e601|Regimen=1}}
- 23:39, 8 January 2020 diff hist +62 Non-small cell lung cancer, BRAF-mutated →Dabrafenib & Trametinib {{#subobject:d08f40|Regimen=1}}
- 23:23, 8 January 2020 diff hist +99 Non-small cell lung cancer, ALK-positive →Variant #2, 750 mg/day fasting {{#subobject:47c6e4|Variant=1}}
- 23:15, 8 January 2020 diff hist +100 Non-small cell lung cancer, ALK-positive →Variant #1, 450 mg/day with food {{#subobject:381ec5|Variant=1}}
- 23:12, 8 January 2020 diff hist +199 Non-small cell lung cancer, ALK-positive →Carboplatin & Pemetrexed {{#subobject:920f46|Regimen=1}}
- 23:06, 8 January 2020 diff hist +123 Non-small cell lung cancer, ALK-positive →Brigatinib monotherapy {{#subobject:93d753|Regimen=1}}
- 22:54, 8 January 2020 diff hist +19 Non-small cell lung cancer, ALK-positive →Genomic Criteria
- 22:53, 8 January 2020 diff hist +19 Non-small cell lung cancer, ALK-positive →Genomic Criteria
- 22:50, 8 January 2020 diff hist +81 Non-small cell lung cancer, ALK-positive →Alectinib monotherapy {{#subobject:b1194c|Regimen=1}}
- 22:45, 8 January 2020 diff hist +92 Non-small cell lung cancer, ALK-positive →Alectinib monotherapy {{#subobject:b1194c|Regimen=1}}
- 04:12, 8 January 2020 diff hist +1,960 Esophageal cancer →Definitive therapy
- 03:07, 8 January 2020 diff hist +190 Esophageal cancer →Nivolumab monotherapy {{#subobject:10ee99|Regimen=1}}
- 03:04, 8 January 2020 diff hist +1,592 Esophageal cancer →Metastatic or locally advanced disease, subsequent lines of therapy
- 13:21, 31 December 2019 diff hist +1,747 Colon cancer →Adjuvant therapy
- 13:58, 30 December 2019 diff hist +1,990 Colon cancer, RAS wild-type →Advanced or metastatic disease, first-line
- 13:23, 30 December 2019 diff hist +2,011 Colon cancer →Regorafenib monotherapy {{#subobject:b6f696|Regimen=1}}
- 23:58, 6 November 2019 diff hist -1 Colorectal cancer, HER2-positive →References
- 23:57, 6 November 2019 diff hist +7,648 N Colorectal cancer, HER2-positive Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' |- |s..."
- 22:36, 6 November 2019 diff hist +1,187 Colorectal cancer, BRAF-mutated
- 07:08, 6 November 2019 diff hist +1,399 Colorectal cancer, BRAF-mutated →Advanced or metastatic disease, second or third-line therapy
- 06:49, 6 November 2019 diff hist -21 Colorectal cancer, BRAF-mutated →Advanced or metastatic disease, BRAF V600E mutation, second or third-line therapy
- 06:46, 6 November 2019 diff hist +1,822 Colorectal cancer, BRAF-mutated